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Lipoprotein(a) as a Potential Causal
Genetic Risk Factor of Cardiovascular Disease
A Rationale for Increased Efforts to Understand
its Pathophysiology and Develop Targeted Therapies
Sotirios Tsimikas, MD,* Jennifer L. Hall, PHD†
La Jolla, California; and Minneapolis, Minnesota
Recent published studies have provided increasing evidence that lipoprotein(a) [Lp(a)] may be a potential
causal, genetic, independent risk factor for cardiovascular disease (CVD). Lp(a) levels 25 mg/dl are present in
30% of Caucasians and 60% to 70% of Blacks. Lp(a) is composed of apolipoprotein B-100 and apolipoprotein
(a) [(apo(a)]. Circulating Lp(a) levels are primarily influenced by the LPA gene without significant dietary or envi-
ronmental effects, mediating CVD risk throughout the patient’s lifetime. Recent clinical outcomes studies, meta-
analyses, and Mendelian randomization studies, in which randomization of Lp(a) levels is achieved through the
random assortment of LPA gene variants thereby removing confounders, have shown that genetically deter-
mined Lp(a) levels are continuously and linearly related to risk of CVD. Currently, Lp(a) pathophysiology is not
fully understood, and specifically targeted therapies to lower Lp(a) are not available. We provide a rationale for
increased basic and clinical investigational efforts to further understand Lp(a) pathophysiology and assess
whether reducing Lp(a) levels minimizes CVD risk. First, a detailed understanding of Lp(a) synthesis and clear-
ance has not been realized. Second, several mechanisms of atherogenicity are known to varying extent, but the
relative contributions of each are not known. Lp(a) may be atherothrombotic through its low-density lipoprotein
moiety, but also through apo(a), including its ability to be retained in the vessel wall and mediate pro-
inflammatory and proapoptotic effects including those potentiated by its content of oxidized phospholipids, and
antifibrinolytic effects. Finally, development of specific Lp(a)-lowering agents to potently lower Lp(a) will allow
testing of mechanistic hypotheses in animal models and the design of randomized clinical trials to assess reduc-
tion in CVD. A convergence of academic, scientific, pharmaceutical, and National Institutes of Health priorities
and efforts can make this a reality in the next decade. (J Am Coll Cardiol 2012;60:716–21) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.038l
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(Cardiovascular disease (CVD) mediated by atherosclerosis
is initiated very early in human life and manifests itself
clinically after a long latent phase of integrative and cumu-
lative insults to the vessel wall by genetic, environmental,
behavioral, and dietary risk factors. A hallmark of athero-
sclerosis is chronic inflammation mediated by innate and
adaptive immune responses in removing the accumulation
of pro-inflammatory substances. These responses are man-
ifested primarily by the presence of activated macrophages,
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accepted April 16, 2012.T-cells, and humoral responses such inflammatory cytokines
(1). Although a variety of pro-inflammatory materials accumu-
ate in the vessel wall, modified and oxidized products of
poB-containing lipoproteins, representing danger-associated
olecular patterns (2), are key mediators of such pro-
nflammatory responses. Without accumulation of modified
ipids in the vessel wall, primary inflammatory mechanisms
ould likely contribute little to clinical manifestations of CVD.
Broadly speaking, there are 4 major categories of lipid
bnormalities in humans: elevated low-density lipoprotein
holesterol (LDL-C), low high-density lipoprotein choles-
erol (HDL-C), elevated triglycerides, and elevated lipopro-
ein(a) [Lp(a)]. LDL-C, HDL-C, and triglyceride levels are
ffected by diet. By contrast, Lp(a) plasma levels are
ediated largely by the LPA gene locus present on chro-
osome 6q22–23, with small-to-negligible effects of diet
3). Lp(a) levels 50 mg/dl represent a prevalence 80th
percentile (reviewed in Nordestgaard et al. [4]), which is
typically considered to be “elevated” for clinical biomarkers.
However, most studies and meta-analyses show an increase
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that Lp(a) levels 25 to 30 mg/dl are present in approx-
imately 30% of Caucasians and 60% to 70% of Blacks
(i.e., 100,000,000 Americans). Because elevated Lp(a)
levels are present at birth, they may potentially contribute to
CVD risk starting very early in life, analogous to other
genetic risk factors.
Although the mortality from CVD has significantly
declined since the 1960s, there is no convincing data that
the development of CVD has declined in proportion. The
residual risk represented by lipid abnormalities remains high
and is the continuing focus of novel treatments for raising
HDL-C and lowering triglycerides. As supported by recent
studies and the current paper by Helgadottir et al. (6) in the
current issue of the Journal, the independent residual risk of
Lp(a) in mediating CVD is substantial and represents a
significant opportunity and potential target of therapy in
reducing the overall risk of CVD even further.
What is Lp(a)? Lp(a) is a circulating lipoprotein composed
of liver-derived apo(a) covalently bound to apoB, which is
similar in lipid composition to apoB of LDL (7). In 1963,
Kare Berg (8) reported the presence of Lp(a) in humans
when searching for antigenic determinants of blood types by
observing that one-third of patients’ plasma reacted to an
antiserum from rabbits immunized with human LDL.
From 1987, Richard Lawn and associates (9) discovered
that the LPA gene, and thus the protein apo(a), was highly
omologous to plasminogen. Plasminogen contains 5 krin-
les and a protease domain that is acted upon by plasmin-
gen activators, either endogenously or therapeutically, to
enerate plasmin and initiate fibrinolysis. Apo(a) has im-
ortant differences compared with plasminogen: 1) apo(a)
as an unpaired cysteine and forms a disulfide bond with
poB to generate the lipoprotein particle Lp(a); 2) it
ontains an inactive protease domain potentially acting as a
ompetitive inhibitor; and 3) it lacks kringles 1 to 3 of
lasminogen, but contains kringle 5 (KV) and 10 subtypes
f KIV, of which KIV-II is present in multiple repeats (over
0 unique isoforms exist), giving LPA/apo(a) the distinc-
ion of being one of the most polymorphic genes/proteins in
ature. In fact, 80% of patients have 2 distinct isoforms, that
s, 2 different-sized circulating Lp(a) particles. Interestingly,
p(a) is only present in humans, apes, and Old World
onkeys, but a second version containing only multiple
opies KIII bound to apoB evolved separately in the
uropean hedgehogs. This suggests that the plasminogen
ene independently remodeled twice during mammalian
volution to produce similar forms of apo(a)/Lp(a) in 2
idely divergent groups of species, perhaps reflecting im-
ortant physiological, though not yet revealed, advantages.
Plasma Lp(a) levels are inversely associated with the
ize of the apo(a) isoforms, which can explain up to 50%
f plasma-level variability. Patients of African ancestry
enerally have 2- to 3-fold higher Lp(a) levels for the
ame number of KIV-II repeats than Caucasians, an
bservation that has not been fully explained (10). A ssecond layer of plasma-level vari-
ability is added by LPA single nu-
cleotide polymorphisms (SNPs)
that can be associated with both
higher and lower Lp(a) levels
(11,12). Significant associations
exist between two LPA variants,
rs10455872 and rs3798220, in-
creased Lp(a) levels, and CVD
with the CVD risk primarily me-
diated by Lp(a) levels rather than
an independent effect of the
SNPs (11,12). These SNPs cor-
relate with a smaller apo(a) iso-
form size and, account for an
additional 36% of the total vari-
ation in Lp(a) levels. The under-
lying mechanisms through which these SNPs result in
higher Lp(a) levels are not known.
Measurement of Lp(a) levels is offered by a variety of
manufacturers, is not fully standardized, and is performed
with several assays, including immunoturbidometry, neph-
elometry, and enzyme-linked immunosorbent assays. Assays
can be reported as nmol/l using a World Health Organiza-
tion–approved, International Federation of Clinical Chem-
istry and Laboratory Medicine reference standard apo(a)
with 21 KIV repeats and value of 107 nmol/l (13). This
assay measures Lp(a) as moles of apo(a) protein using
specific monoclonal antibodies (14), is independent of
isoform size, will facilitate comparison among studies, and
should be the preferred method. Lp(a) can also be measured
as mg/dl representing the entire mass of Lp(a) (protein,
lipid, and carbohydrate). In assays reporting data as mg/dl,
despite use of polyclonal antibodies independent of isoform
size, apo(a) size-dependent bias can be seen with the assay
calibrators, which are generally pooled plasma samples that
putatively represent all the different isoforms in the plasma
being measured. Therefore, these assays must be validated
with reference standards. Lp(a) can also be measured as
Lp(a) “cholesterol” in mg/dl and assayed using quantifica-
tion gradient analysis, but the published database for the
predictive value of this assay is significantly smaller than the
others. In general, nmol/l can be converted to mg/dl by
dividing by 2.8, and Lp(a) “cholesterol” values are normal
when 10 mg/dl. See Koschinsky and Marcovina (15) for a
detailed review on Lp(a) measurements.
What is the contribution of Lp(a) to genetic risk of CVD
and specifically atherothrombosis? The study from Hel-
gadottir et al. (6) encompassing nearly 45,000 patients,
published in this issue of the Journal, suggests that LPA
ariants rs10455872 and rs3798220, defined as an LPA risk
core by combining their effects, are associated with angio-
raphically determined earlier onset of coronary artery
isease (p  4.8  1012), peripheral arterial disease (p 
.9  1014), aortic aneurysm (p  6.0 105), and ischemic
Abbreviations
and Acronyms
apo(a)  apolipoprotein(a)
CVD  cardiovascular
disease
HDL-C  high-density
lipoprotein cholesterol
K  kringle
LDL-C  low-density
lipoprotein cholesterol
Lp(a)  lipoprotein(a)
OxPL  oxidized
phospholipids
SNP  single nucleotide
polymorphismtroke subtype large artery atherosclerosis (p  6.7  104).
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also in African-Americans, which has been an area of
controversy (16). As opposed to the effect on anatomical
presence of CVD, there was no effect of these SNPs on
venous thrombosis or early atherogenesis as measured by
carotid intima-media thickness, suggesting that the major
effect of Lp(a) is on advanced plaque development and
destabilization rather than thrombosis. There was also no
effect of LPA variants on ischemic stroke subtypes,
cardioembolism, small vessel disease, or intracranial an-
eurysm. However, as noted by the authors (6), the study
may have been underpowered to detect significance
within these groups. Finally, Lp(a) levels were not
measured, which would have been useful to tease out the
effect of the SNPs on Lp(a) levels and their respective
effects on CVD risk.
Within the last few years, multiple studies have shown
that elevated Lp(a) levels are independently and linearly
predictive of future CVD (5,12,16–19). For example, in the
Copenhagen City Heart Studies of 42,000 subjects with a
15-year follow-up (19) using a Mendelian randomization
approach, Lp(a) levels were related to the number of
genetically determined apo(a) KIV-II repeats, with an
inverse association between decreasing number of KIV-II
repeats in the LPA gene and higher plasma Lp(a) levels. In
turn, higher levels were continuously related to risk of
myocardial infarction. Although Mendelian randomization
studies are not a proxy for randomized controlled trials in
proving causality, they provide supporting evidence for a
potential role of Lp(a) as a risk factor for CVD.
What are the biological mechanistic underpinnings of
the atherogenicity of Lp(a)? The putative physiological
role of Lp(a), if any, remains undefined, but it has been
postulated to have roles in tissue healing, innate immunity,
and infection. Apo(a) has potent lysine binding domains,
similar to those on plasminogen, and binds to damaged
endothelial cells and exposed or injured subendothelial
matrix proteins, and delivers cholesterol for cell membrane
growth. In a physiological setting without the presence of
CVD risk factors, this property (now perhaps vestigial) may
have contributed to the selection of Lp(a) in primates.
Alternatively, it may also have been a random occurrence of
gene duplication, although this appears less likely, having
arisen independently 2 separate times. However, in a setting
of CVD risk factors and increased oxidative and inflamma-
tory stress present in our current societies, Lp(a) is clearly
proatherogenic when levels are elevated. One mechanism of
atherogenicity is through the LDL component. However,
apo(a) alone, and Lp(a) as a lipoprotein, have additional
potential contributions (20), including increasing endothe-
lial cell permeability and expression of adhesion molecules,
promoting smooth muscle cell proliferation, enhancing
monocyte entry and retention in the vessel wall, macrophage
foam cell formation, promoting release of pro-inflammatory
IL-8 levels, and antifibrinolytic effects, as a carrier of
pro-inflammatory and proatherogenic OxPL (21). Impor-tantly, a recent study has documented that Lp(a) and OxPL
mediate macrophage apoptosis in endoplasmic reticulum–
stressed macrophages by signaling through the CD36/
TLR2 receptor pathway to initiate ERK activation. ERK
stimulates lysosomal p47 clustering and NADPH oxidase–
dependent generation of reactive oxygen species (Fig. 1)
(22). This is also consistent with data from our laboratory
showing the presence of OxPL and Lp(a) in advanced
“vulnerable” human carotid artery thin-cap fibroatheroma,
which is the precursor to plaque rupture, demonstrating
concomitant immunostaining for OxPL and apo(a) (23).
Since macrophage apoptosis is a key component of plaque
vulnerability, these data provide supporting evidence of
Lp(a) as a risk factor for development of advanced, clinically
relevant atherosclerotic lesions.
Interestingly, recent data demonstrate that OxPL are also
present on plasminogen, which seems to represent the other
major source of OxPL in plasma proteins. However, when
present on plasminogen, OxPL actually potentiate, rather
than inhibit fibrinolysis, and would be expected to be
protective against excess thrombus formation (24). This
suggests context-dependent and carrier-dependent roles of
OxPL in mediating atherothrombosis (25).
A key component of the atherogenicity of Lp(a) has been
the contribution of OxPL. OxPL are immunogenic and
accumulate in atherosclerotic lesions and mediate plaque
destabilization. Elevated levels of OxPL on apoB are asso-
ciated with the presence and progression of coronary artery
disease and peripheral arterial disease, predict new CVD
events in prospective studies, and provide enhanced predic-
tive value in models with established risk factors or Fra-
mingham Risk Score estimates (17,18,26) (reviewed in
Taleb et al. [21]). Although strong in vitro data exist to
support the role of Lp(a) in inhibiting fibrinolysis, including
alteration of fibrin clot architecture, reducing plasmin gen-
eration and tissue factor pathway inhibitor and plasminogen
activator-1 levels, the findings in the current study seem to
refute a strong in vivo effect.
What are the gaps in the basic understanding of Lp(a)
biology? The pathways regulating the synthesis and degra-
dation of Lp(a) are not well understood. Lp(a) in plasma
represents the summation of the production of apo(a) from
both chromosomes. Lp(a) levels generally do not change
significantly starting from a few months after birth unless
there is an acute phase response, in which case they can rise
abruptly (21). Because smaller apo(a) isoforms can be
generated more quickly per unit time, small isoforms are
associated with higher plasma Lp(a) levels. Clearance of
Lp(a) is not well understood, but the LDL receptor or
isoform size does not appear to be a main determinant of
clearance. Putative receptors for Lp(a) have been proposed,
as well as re-circulation (on/off) of apo(a) among LDL
particles. Free apo(a) is not usually present in humans,
except in patients with advanced renal failure, although they
accumulate large rather than small isoforms. However,
apo(a) fragments can be found in the urine of patients with
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as 1 clearance mechanism. A better understanding of the
basic mechanisms of the production and metabolism of
Lp(a) will be important in understanding Lp(a) biology and
in defining the effect of future therapeutic agents.
Unlike the recent human data, data in animal models to
define the atherogenicity of Lp(a) have been inconsistent
due to the following limitations: 1) Lp(a) is not naturally
present in experimental models such as mice and rabbits. To
produce such models, double transgenic animals overex-
pressing both apo(a) and human apoB-100 [apo(a) does not
bind to mouse apoB and therefore cannot generate true
Lp(a) particles] need to be generated; 2) most constructs
have cDNA rather than genomic DNA and therefore do
not have the natural promoters; 3) most Lp(a) transgenic
models, until recently (27), have expressed levels of Lp(a)
that are considered in the normal range of humans (25
mg/dl), and usually only 1 isoform is expressed, whereas
over 40 isoforms exist in humans. Therefore, lack of
appropriate experimental models has led to inadequate
testing of hypotheses. New approaches to address these gaps
in basic research are needed, including studies to understand
apo(a) synthesis and metabolism in vivo, pro-inflammatory
effects, novel animal models with genomic apo(a) con-
structs, basic studies on fibrinolytic and platelet effects,
effects on macrophage apoptosis and foam cells formation,
and the role of Lp(a)-associated components, such as OxPL
and Lp-PLA2 on atherogenicity (17,18,28). The new focus
Figure 1 Model Depicting Development of Macrophage Apopto
Major Factor in Plaque Vulnerability, by Lp(a)/OxPL D
Various ligands for CD36 such as lipoprotein(a) [Lp(a)], oxidized phospholipids (Ox
through CD36 and TLR2/6 to initiate ERK activation. ERK stimulates lysosomal p4
(ROS) known as the oxidative burst. ROS generation is sustained by the presence
phage apoptosis induced by this pathway. Reprinted, with permission, from Seimofrom the National Institutes of Health on TranslationalResearch could significantly benefit our basic understanding
of the role of Lp(a) in mediating atherosclerosis and
establish partnerships with pharmaceutical companies to
define small molecules as therapies.
What are the gaps in clinical medicine and the rationale
for developing targeted and specific therapies for lowering
plasma Lp(a) levels? Despite the strong clinical data,
randomized clinical trials documenting that lowering Lp(a)
levels leads to clinical benefit have not been performed.
Because specific and effective agents do not currently exist
without affecting other lipoproteins, it is not going to be
possible to test this hypothesis without development of
novel Lp(a)-lowering agents. It is known that niacin and
estrogens lower Lp(a) up to 30% but that statins either have
no effect or increase Lp(a) levels, sometimes significantly
(21). Recently, it has been shown that cholesteryl ester
transport protein (CETP) inhibitors, thyroid mimetics,
PCSK9 inhibitors, aspirin, and the antisense oligonucleo-
tide to apoB, mipomersen (29), lower Lp(a) levels. How-
ever, in all these studies, Lp(a) levels were lowered in
conjunction with changes in other lipoproteins. In the
Women’s Health Study, carriers of the LPA variant
rs3798220 had doubling of cardiovascular risk and appeared
to benefit more from aspirin than noncarriers (30). Addi-
tionally, the underlying mechanisms of Lp(a) lowering of
these agents are not fully defined. We have recently dem-
onstrated that a specific antisense oligonucleotide directed
to KIV-II repeats lowers apo(a) mRNA and apo(a) plasma
ER Stress
xidized low-density lipoprotein (OxLDL), and saturated fatty acids (sat FAs) signal
tering and NADPH oxidase–dependent generation of reactive oxygen species
endoplasmic reticulum (ER) stress–inducing agent and is essential for macro-
l. (22).sis, a
uring
PL), o
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n et alevels by 85% in apo(a)-transgenic mice, with minor effects
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antisense oligonucleotide in which a mechanistic under-
standing of its action is known or other specific Lp(a)-
lowering agents such as farnesoid X receptor agonists (31)
will ultimately allow the testing of the hypothesis that
elevated Lp(a) levels can be lowered substantially with
concomitant reduction of cardiovascular events. The design
of such a study would have to take into account LDL-C
levels and other risk factors, but can be proposed and should
be feasible with more specific and powerful Lp(a)-lowering
agents. Initial potential subjects for such a trial could be
patients with elevated Lp(a) (25 to 30 mg/dl) and acute
coronary syndromes that have high recurrence of repeat
events, patients with familial hypercholesterolemia who
generally have concomitantly high Lp(a) levels, more diffi-
cult to control LDL-C, and are at high risk for CVD events,
and patients with mixed dyslipidemias and strong family
history of CVD and patients with high Lp(a) and recurrent
events despite maximal tolerated therapies. In conjunction
with clinical trials, further validation of methodologies and
standards in measuring and reporting Lp(a) are needed to
optimize comparisons among studies (14). The recent
recommendations of the European Atherosclerosis Society
Consensus Panel (4) have suggested screening for elevated
Lp(a) in those at intermediate or high CVD/coronary heart
disease (CHD) risk, a desirable level 50 mg/dl as a
function of global cardiovascular risk, and use of niacin for
Lp(a) and CVD risk reduction. The latter 2 suggestions
may be seen as controversial, as the evidence for niacin is
only available from retrospective analyses, and the proper
target for Lp(a) levels has not been established, but they
provided a framework for ongoing debate and awareness of
Lp(a) as a potential CVD risk factor. The National Lipid
Association (32) has also recently provided a consensus
document on screening moderate to high-risk patients for
elevated Lp(a) levels. The recommendations of both of
these societies will broaden the discussion of the role of
Lp(a) in clinical care to detect and treat patients at risk and
in investigational efforts to develop novel therapeutic agents.
Conclusions
The journey of Lp(a) as a clinically relevant lipoprotein over
the last 50 years has evolved from an antigenic determinant
in blood type, to a putative cardiovascular risk factor, to an
independent, genetic risk marker of CVD. The next phase
is to test causality as a risk factor by improved understanding
of its biological functions and the development of novel and
specific targeted therapies to assess reduction of cardiovas-
cular outcomes and residual risk. We urge increased efforts
to study the atherogenicity of Lp(a) by the academic and
scientific communities, grant support by the National Insti-
tutes of Health and American Heart Association, and
investment by the pharmaceutical industry. We look for-
ward to the day when all lipoprotein disorders will haveeffective therapies to improve the quality of care for indi-
viduals and decrease risk of CVD.
Reprint requests and correspondence: Dr. Sotirios Tsimikas,
Vascular Medicine Program, University of California San Diego,
9500 Gilman Drive, La Jolla, California 92993-0682. E-mail:
stsimikas@ucsd.edu.
REFERENCES
1. Libby P, Ridker PM, Hansson GK. Progress and challenges in
translating the biology of atherosclerosis. Nature 2011;473:317–25.
2. Miller YI, Choi SH, Wiesner P, et al. Oxidation-specific epitopes are
danger-associated molecular patterns recognized by pattern recogni-
tion receptors of innate immunity. Circ Res 2011;108:235–48.
3. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr
Opin Lipidol 1999;10:225–36.
4. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a
cardiovascular risk factor: current status. Eur Heart J 2010;31:2844–53.
5. The Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry
PL, et al. Lipoprotein(a) concentration and the risk of coronary heart
disease, stroke, and nonvascular mortality. JAMA 2009;302:412–23.
6. Helgadottir, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein (a)
genétic sequence variants associated with systemic atherosclerosis and
coronary atherosclerosis burden but not with venous thromboembo-
lism. J Am Coll Cardiol 2012;60:722–9.
7. Dube JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a):
more interesting than ever after 50 years. Curr Opin Lipidol 2012;23:
133–40.
8. Berg K. A new serum type system in man—the LP system. Acta
Pathol Microbiol Scand 1963;59:369–382.
9. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of
human apolipoprotein(a) is homologous to plasminogen. Nature
1987;330:132–7.
10. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized
phospholipids on apolipoprotein B-100 particles to race/ethnicity,
apolipoprotein(a) isoform size, and cardiovascular risk factors: results
from the Dallas Heart Study. Circulation 2009;119:1711–9.
11. Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the
apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc
Genet 2011;4:565–73.
12. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated
with Lp(a) lipoprotein level and coronary disease. N Engl J Med
2009;361:2518–28.
13. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material
proposed by the International Federation of Clinical Chemistry and
Laboratory Medicine to evaluate analytical methods for the determi-
nation of plasma lipoprotein(a). Clin Chem 2000;46:1956–67.
14. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the
National Heart, Lung, and Blood Institute Workshop on Lipopro-
tein(a) and Cardiovascular Disease: recent advances and future direc-
tions. Clin Chem 2003;49:1785–96.
15. Koschinsky ML, Marcovina S, editors. Lipoprotein(a). Philadelphia,
PA: Saunders Elsevier, 2009.
16. Virani SS, Brautbar A, Davis BC, et al. Associations between
lipoprotein(a) levels and cardiovascular outcomes in black and white
subjects: the Atherosclerosis Risk in Communities (ARIC) study.
Circulation 2012;125:241–9.
17. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipopro-
tein(a), lipoprotein-associated phospholipase A2 activity, and 10-year
cardiovascular outcomes: prospective results from the Bruneck study.
Arterioscler Thromb Vasc Biol 2007;27:1788–95.
18. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomark-
ers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am
Coll Cardiol 2010;56:946–55.
19. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG.
Genetically elevated lipoprotein(a) and increased risk of myocardial
infarction. JAMA 2009;301:2331–9.
20. Koschinsky ML, Marcovina SM. Structure-function relationships in
apolipoprotein(a): insights into lipoprotein(a) assembly and pathoge-
nicity. Curr Opin Lipidol 2004;15:167–74.
721JACC Vol. 60, No. 8, 2012 Tsimikas and Hall
August 21, 2012:716–21 Lipoprotein(a) as a Potential Causal Genetic Risk Factor21. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on
apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a bio-
marker predicting cardiovascular disease and cardiovascular events.
Biomark Med 2011;5:673–694.
22. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and
lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages un-
dergoing endoplasmic reticulum stress. Cell Metab 2010;12:467–82.
23. Ravandi A, Harkewicz R, Leibundgut G, et al. Identification of
oxidized phospholipids and cholesteryl esters in embolic protection
devices post percutaneous coronary, carotid and peripheral interven-
tions in humans. Presented at: ATVB 2011 Scientific Sessions. April
28–30, 2011; Chicago, IL.
24. Leibundgut G, Arai K, Orsoni A, et al. Oxidized phospholipids are
present on plasminogen, affect fibrinolysis, and increase following
acute myocardial infarction. J Am Coll Cardiol 2012;59:1426–37.
25. Libby P. Counterregulation rules in atherothrombosis. J Am Coll
Cardiol 2012;59:1438–40.
26. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a)
lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46–57.
27. Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers
plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic
mice. J Am Coll Cardiol 2011;57:1611–21.28. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of
lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in
atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc
Biol 2007;27:2094–9.
29. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein
B synthesis inhibitor, for lowering of LDL cholesterol concentrations
in patients with homozygous familial hypercholesterolaemia: a ran-
domised, double-blind, placebo-controlled trial. Lancet 2010;375:
998–1006.
30. Chasman DI, Shiffman D, Zee RYL, et al. Polymorphism in the
apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease,
and low-dose aspirin therapy. Atherosclerosis 2009;203:371–6.
31. Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor
represses hepatic human APOA gene expression. J Clin Invest
2011;121:3724–34.
32. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of
inflammatory markers and advanced lipoprotein testing: advice
from an expert panel of lipid specialists. J Clin Lipidol 2011;5:
338 – 67.Key Words: cardiovascular disease y Lp(a) y therapy.
